Cretostimogene grenadenorepvec (CG0070) clinical studies
Our lead candidate, cretostimogene grenadenorepvec (CG0070), is a targeted oncolytic intravesically delivered immunotherapy agent that is currently in a Phase 3 trial for the treatment of BCG-unresponsive NMIBC. It is also in Phase 2 study in combination with KEYTRUDA® A (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene in combination with OPDIVO® B (nivolumab). We are planning other studies in bladder cancer.
BOND-003 monotherapy
BCG-Unresponsive, High Risk NMIBC
CORE-001 in combination
CG0070 + KEYTRUDA® BCG-Unresponsive, High Risk NMIBC
CORE-002 in combination
CG0070 + OPDIVO® Neoadjuvant in MIBC
Well Positioned to Tackle Different Stages of Bladder Cancer
Other studies are planned in the near future
A KEYTRUDA is a registered trademark of Merck Sharp and Dohme.
B OPDIVO is a registered trademark of Bristol-Myers Squibb Company.
